

# Global Irritable Bowel Syndrome Treatment Market Size study, by Type (IBS-C, IBS-D), Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza), Distribution Channel, and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G1221434DF28EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G1221434DF28EN

## Abstracts

Global Irritable Bowel Syndrome Treatment Market is valued approximately at USD 3.35 billion in 2023 and is anticipated to grow with a steady CAGR of more than 8.80% over the forecast period 2024-2032. Irritable Bowel Syndrome (IBS), a chronic gastrointestinal disorder characterized by abdominal discomfort, bloating, and altered bowel habits, continues to pose a significant healthcare burden worldwide. The emergence of condition-specific therapeutics such as Linzess (linaclotide), Viberzi (eluxadoline), and Xifaxan (rifaximin) has revolutionized the treatment framework, replacing general symptomatic approaches with mechanistically targeted interventions. As clinical understanding of IBS pathophysiology advances, biopharmaceutical firms are increasingly leveraging biomarkers and patient stratification to tailor drug development for IBS-C (constipation predominant) and IBS-D (diarrhea predominant) subtypes, thereby improving therapeutic precision and patient outcomes.

The robust growth of the IBS treatment market is driven by increasing disease prevalence, amplified by lifestyle factors such as dietary irregularities, rising stress levels, and sedentary habits, particularly in urban regions. Additionally, the growing adoption of over-the-counter (OTC) and prescription medications has expanded treatment access. Marketing collaborations between drug manufacturers and healthcare providers have enhanced awareness and diagnosis rates, fostering early intervention. However, the market is not without challenges. Adverse side effects of certain drugs, high treatment costs, and limited drug efficacy for some patient cohorts often undermine adherence and satisfaction. These obstacles are gradually being addressed through reformulated drug profiles, enhanced patient education, and post-marketing surveillance

initiatives.

Advancements in microbiome-targeted therapies and serotonin receptor modulators signal the next frontier in IBS treatment. Pharmaceutical companies are also focusing on digital therapeutics, using mobile applications and AI algorithms to help monitor symptoms and medication compliance in real time. This convergence of pharmacology and technology is fostering a more comprehensive, patient-centric approach to IBS management. Meanwhile, health insurers are increasingly receptive to reimbursing newer medications based on demonstrated quality-of-life improvements, which in turn is motivating investment in novel product pipelines.

Geographically, North America leads the global IBS treatment market, with the United States at the forefront due to its well-established healthcare systems, proactive diagnostic programs, and a high prevalence of IBS. Europe holds the second-largest market share, supported by strong regulatory frameworks and the widespread availability of specialized gastrointestinal treatments in countries such as Germany, the UK, and France. The Asia Pacific region is poised for the fastest growth, driven by increasing disease awareness, dietary transitions, and expanding healthcare infrastructure in emerging economies like China, India, and Japan. Latin America and the Middle East & Africa also offer considerable growth potential, aided by gradual shifts in dietary habits and growing access to medical treatment.

Major market player included in this report are:

Allergan plc

AbbVie Inc.

Takeda Pharmaceutical Company Limited

Ironwood Pharmaceuticals, Inc.

AstraZeneca plc

Novartis AG

Synergy Pharmaceuticals Inc.

Salix Pharmaceuticals

Sebela Pharmaceuticals

Synthetic Biologics, Inc.

Ardelyx, Inc.

Astellas Pharma Inc.

Sucampo Pharmaceuticals Inc.

Progenity, Inc.

Lexicon Pharmaceuticals, Inc.

The detailed segments and sub-segment of the market are explained below:

#### By Type

IBS-C

IBS-D

#### By Product

Xifaxan

Linzess/Constella

Viberzi

Amitiza

#### By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region: North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows: Historical year – 2022 Base year – 2023  
Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

## Contents

### **1. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET EXECUTIVE SUMMARY**

- 1.1. Global IBS Treatment Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
  - 1.3.1. By Type (IBS-C, IBS-D)
  - 1.3.2. By Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza)
  - 1.3.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

### **2. GLOBAL IBS TREATMENT MARKET DEFINITION AND RESEARCH ASSUMPTIONS**

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
  - 2.3.1. Inclusion & Exclusion
  - 2.3.2. Limitations
  - 2.3.3. Supply Side Analysis
    - 2.3.3.1. Availability
    - 2.3.3.2. Infrastructure
    - 2.3.3.3. Regulatory Environment
    - 2.3.3.4. Market Competition
    - 2.3.3.5. Economic Viability (Patient Perspective)
  - 2.3.4. Demand Side Analysis
    - 2.3.4.1. Regulatory Frameworks
    - 2.3.4.2. Technological Advancements
    - 2.3.4.3. Environmental Considerations
    - 2.3.4.4. Patient Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

### **3. GLOBAL IBS TREATMENT MARKET DYNAMICS**

#### 3.1. Market Drivers

- 3.1.1. Rising Disease Prevalence Driven by Lifestyle and Urbanization
- 3.1.2. Expanded Access via Prescription and OTC Therapeutics
- 3.1.3. Enhanced Diagnosis and Awareness through Provider Collaborations

#### 3.2. Market Challenges

- 3.2.1. Adverse Side-Effect Profiles Limiting Adherence
- 3.2.2. High Treatment Costs and Reimbursement Hurdles
- 3.2.3. Variable Efficacy across Patient Subgroups

#### 3.3. Market Opportunities

- 3.3.1. Microbiome-Targeted Therapeutics
- 3.3.2. Serotonin Receptor Modulators and Novel Mechanistic Agents
- 3.3.3. Digital Therapeutics and Real-Time Symptom Monitoring
- 3.3.4. Growing Insurer Reimbursement for Quality-of-Life Improvements

### **4. GLOBAL IBS TREATMENT MARKET INDUSTRY ANALYSIS**

#### 4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Porter's Five Forces Impact Analysis

#### 4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

#### 4.3. Top Investment Opportunities

#### 4.4. Top Winning Strategies

#### 4.5. Disruptive Trends

#### 4.6. Industry Expert Perspectives

#### 4.7. Analyst Recommendation & Conclusion

## **5. GLOBAL IBS TREATMENT MARKET SIZE & FORECASTS BY TYPE (2022–2032)**

### 5.1. Segment Dashboard

5.2. IBS-C Revenue Trend Analysis, 2022 & 2032 (USD Million)

5.3. IBS-D Revenue Trend Analysis, 2022 & 2032 (USD Million)

## **6. GLOBAL IBS TREATMENT MARKET SIZE & FORECASTS BY PRODUCT (2022–2032)**

### 6.1. Segment Dashboard

6.2. Xifaxan Revenue Trend Analysis, 2022 & 2032 (USD Million)

6.3. Linzess/Constella Revenue Trend Analysis, 2022 & 2032 (USD Million)

6.4. Viberzi Revenue Trend Analysis, 2022 & 2032 (USD Million)

6.5. Amitiza Revenue Trend Analysis, 2022 & 2032 (USD Million)

## **7. GLOBAL IBS TREATMENT MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL (2022–2032)**

### 7.1. Segment Dashboard

7.2. Hospital Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million)

7.3. Retail Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million)

7.4. Online Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million)

## **8. GLOBAL IBS TREATMENT MARKET SIZE & FORECASTS BY REGION (2022–2032)**

### 8.1. North America IBS Market

8.1.1. U.S. IBS Market

8.1.2. Canada IBS Market

### 8.2. Europe IBS Market

8.2.1. UK IBS Market

8.2.2. Germany IBS Market

8.2.3. France IBS Market

8.2.4. Spain IBS Market

8.2.5. Italy IBS Market

8.2.6. Rest of Europe IBS Market

### 8.3. Asia Pacific IBS Market

8.3.1. China IBS Market

8.3.2. India IBS Market

- 8.3.3. Japan IBS Market
- 8.3.4. Australia IBS Market
- 8.3.5. South Korea IBS Market
- 8.3.6. Rest of APAC IBS Market
- 8.4. Latin America IBS Market
  - 8.4.1. Brazil IBS Market
  - 8.4.2. Mexico IBS Market
  - 8.4.3. Rest of LATAM IBS Market
- 8.5. Middle East & Africa IBS Market
  - 8.5.1. Saudi Arabia IBS Market
  - 8.5.2. South Africa IBS Market
  - 8.5.3. Rest of MEA IBS Market

## **9. COMPETITIVE INTELLIGENCE**

- 9.1. Key Company SWOT Analysis
  - 9.1.1. Allergan plc
  - 9.1.2. AbbVie Inc.
  - 9.1.3. Takeda Pharmaceutical Company Limited
- 9.2. Top Market Strategies
- 9.3. Company Profiles
  - 9.3.1. Allergan plc
    - 9.3.1.1. Key Information
    - 9.3.1.2. Overview
    - 9.3.1.3. Financial (Subject to Data Availability)
    - 9.3.1.4. Product Summary
    - 9.3.1.5. Market Strategies
  - 9.3.2. Ironwood Pharmaceuticals, Inc.
  - 9.3.3. AstraZeneca plc
  - 9.3.4. Novartis AG
  - 9.3.5. Synergy Pharmaceuticals Inc.
  - 9.3.6. Salix Pharmaceuticals
  - 9.3.7. Sebelo Pharmaceuticals
  - 9.3.8. Synthetic Biologics, Inc.
  - 9.3.9. Ardelyx, Inc.
  - 9.3.10. Astellas Pharma Inc.
  - 9.3.11. Sucampo Pharmaceuticals Inc.
  - 9.3.12. Progenity, Inc.
  - 9.3.13. Lexicon Pharmaceuticals, Inc.

## **10. RESEARCH PROCESS**

### 10.1. Research Process Overview

10.1.1. Data Mining

10.1.2. Analysis

10.1.3. Market Estimation

10.1.4. Validation

10.1.5. Publishing

### 10.2. Research Attributes

## I would like to order

Product name: Global Irritable Bowel Syndrome Treatment Market Size study, by Type (IBS-C, IBS-D), Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza), Distribution Channel, and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G1221434DF28EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1221434DF28EN.html>